A2A-04 is under clinical development by A2A Pharmaceuticals and currently in Phase I for Peritoneal Cancer. According to GlobalData, Phase I drugs for Peritoneal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how A2A-04’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

A2A-04 overview

A2A-04 is under development for the treatment of solid tumor, leukemia, triple-negative breast cancer (TNBC), high-grade serous ovarian carcinoma (HGSOC), primary peritoneal cancer, fallopian tube cancer and endometrial cancer. It acts by targeting the stimulator of interferon genes protein (STING). The drug candidate is developed based on Systematic Combinatorial Unification of chemical groups into Libraries against a Pharmacological Target (SCULPT) therapeutic design platform. It is administered through oral route.

A2A Pharmaceuticals overview

A2A Pharmaceuticals (A2A) is a biotechnology company focused on the development of small molecule therapeutics for life-threatening diseases including cancer, bacterial infections and muscular dystrophy. Its proprietary technology SCULPT, a therapeutic design methodology inhibits protein-protein interactions and other enzymes that enable the design and development of novel small molecules to match the unique topological features of disease targets. A2A pipeline antibiotic programs include MML-Melin against Leukemia; Yap-Tead for solid tumors; additional programs CLK, STING targeting tumor myeloid cells; and LpxC targeting cancer, Duchenne muscular dystrophy (DMD) and gram-negative bacterial species. The company partnered with Biomea Healthcare, Novartis and Proctor & Gamble to design drug candidates for cardiovascular and cancer targets. A2A is headquartered in New York City, New York, the US.

For a complete picture of A2A-04’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.